Cencora, Inc. (COR) Financial Statements
Historical financial data — 13 statements covering FY2023–FY2025
Cencora is one of three leading domestic pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, an...
Cencora, Inc.'s revenue increased 9.3% year over year, from $293.96B to $321.33B.
Net income increased 3.0% over the same period, from $1.51B to $1.55B.
Total debt increased by 74.6% to $7.66B.
The debt-to-equity ratio stands at 5.08, indicating a high leverage profile.
Operating cash flow grew 11.2% to $3.88B.
Cencora, Inc. maintains a moderate net profit margin of 0.5%.
Recent Financial Statements
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q1 FY2024 | $72.25B-62.6% | $601.5M | $2.47B | $822.9M | $885.2M | $64.69B | $4.78B | $911.7M |
| Q2 FY2024 | $140.67B+94.7% | $1.02B | $5.01B | $1.38B | $6.7M | $63.87B | $5.25B | $1.08B |
| Q3 FY2024 | $214.91B+52.8% | $1.51B | $7.42B | $2.05B | $2.48B | $66.77B | $4.73B | $925.2M |
| Q1 FY2025 | $81.49B-62.1% | $488.6M | $2.56B | $706.3M | $-2.72B | $69.05B | $8.15B | $226.6M |
| Q2 FY2025 | $156.94B+92.6% | $1.21B | $5.62B | $1.74B | $632.5M | $71.19B | $7.86B | $1.01B |
| Q3 FY2025 | $237.60B+51.4% | $1.89B | $8.52B | $2.61B | $741.7M | $73.96B | $8.24B | $1.98B |
| Q1 FY2026 | $85.93B-63.8% | $559.6M | $3.07B | $760.4M | $-2.31B | $78.36B | $7.92B | $1.91B |
| Q2 FY2026 | $164.29B+91.2% | $2.20B | $6.66B | $1.90B | $-966.5M | $81.65B | $12.39B | $3.40B |
Balance Sheet Summary (Latest Period)
Total Assets
$76.59B
Total Liabilities
$75.08B
Total Equity
$1.51B
Cash & Equivalents
$4.36B
Total Debt
$7.66B
Current Assets
$52.24B
Current Liabilities
$57.82B
Retained Earnings
$6.53B